Hydrocortisone May Lower Severe CAP Mortality
Network meta-analysis suggests hydrocortisone may offer mortality and ventilation benefits, although evidence certainty remained low.
-
By
-
Andrea Surnit
-
May 11, 2026
-
Clinical Scorecard: Hydrocortisone May Lower Severe CAP Mortality
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Hydrocortisone associated with lower all-cause mortality compared to placebo; other corticosteroids did not show this effect. |
| Target Population | |
| Care Setting | |
Key Highlights
- Findings based on indirect comparisons; low certainty of evidence due to imprecision and heterogeneity.
Guideline-Based Recommendations
Diagnosis
Management
- Consider hydrocortisone for severe CAP patients; however, current treatment guidelines remain unchanged due to low certainty of evidence.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with severe CAP requiring intensive care.
Low-to-moderate doses and short courses of hydrocortisone may reduce mortality and mechanical ventilation needs.
Clinical Best Practices
- Use hydrocortisone cautiously in severe CAP patients; interpret subgroup analyses with caution due to limited statistical power.
Related Resources & Content
